Below is my email to Adam Feurstein, and his respo
Post# of 153886
(Total Views: 1044)
Posted On: 08/10/2020 2:48:36 PM
Below is my email to Adam Feurstein, and his response:
Hello___ -- Thanks for reaching out. I don't comment on my ongoing reporting work.
Adam
On Mon, Aug 10, 2020 at 2:26 PM _____________ wrote:
Adam:
I have read on a message board that you sent an email to Olive, a person acting on behalf of Holly Kennedy, in which you stated as follows:
“Olive—I’m a reporter with STAT, a digital media company that covers health, medicine, and life sciences. I’m interested in speaking with you about Holly Kennedy and her decision to be treated with Leronlimab, despite any clinical evidence of efficacy in treating TNBC. Your posts suggest she’s been helped by Leronlimab, yet she was hospitalized soon after returning to Ireland. It seems like her condition has worsened, not improved. What evidence is there that Leronlimab has helped her? Do you know if Holly has pursued treatment with Trodelvy, for instance, which was recently approved in the US for advanced TNBC? Are you worried at all that you and Holly are being exploited by people promoting Leronlimab and Cytodyn for financial reasons? I’d like to speak with you if you have the time. Thank you—Adam Feurstein.”
As a STAT News subscriber, and Cytodyn shareholder, I have two questions for you:
First, did you in fact send this email?
Second, if you did send this email, what was the reason you did so?
I look forward to your prompt reply.
Thank you,
____
Hello___ -- Thanks for reaching out. I don't comment on my ongoing reporting work.
Adam
On Mon, Aug 10, 2020 at 2:26 PM _____________ wrote:
Adam:
I have read on a message board that you sent an email to Olive, a person acting on behalf of Holly Kennedy, in which you stated as follows:
“Olive—I’m a reporter with STAT, a digital media company that covers health, medicine, and life sciences. I’m interested in speaking with you about Holly Kennedy and her decision to be treated with Leronlimab, despite any clinical evidence of efficacy in treating TNBC. Your posts suggest she’s been helped by Leronlimab, yet she was hospitalized soon after returning to Ireland. It seems like her condition has worsened, not improved. What evidence is there that Leronlimab has helped her? Do you know if Holly has pursued treatment with Trodelvy, for instance, which was recently approved in the US for advanced TNBC? Are you worried at all that you and Holly are being exploited by people promoting Leronlimab and Cytodyn for financial reasons? I’d like to speak with you if you have the time. Thank you—Adam Feurstein.”
As a STAT News subscriber, and Cytodyn shareholder, I have two questions for you:
First, did you in fact send this email?
Second, if you did send this email, what was the reason you did so?
I look forward to your prompt reply.
Thank you,
____
(4)
(0)CytoDyn Inc (CYDY) Stock Research Links
The Lawman
style="color:red">The Lawman"color:red">The Lawman:red">The LawmanThe Lawmanspan>Lawmanawmanimg]